Vemurafenib As First Treatment of Hairy Cell Leukemia
نویسندگان
چکیده
منابع مشابه
Treatment of hairy-cell leukemia.
AIRY CELL LEUKEMIA (HCL), or leukemic reticuH loendotheliosis, is a chronic lymphoproliferative disease that was first described as a distinct clinicopathologic entity by Bouroncle et a1 in 1958.' It is characterized by mononuclear cells of B-lymphocyte origin in the peripheral blood that have prominent cytoplasmic projections staining with tartrate-resistant acid phosphatase' and by its typica...
متن کاملHairy cell leukemia-variant.
Hairy cell leukaemia variant is a very rare chronic lymphoproliferative disorder and is closely related to hairy cell leukemia. We hereby describe a case of hairy cell leukaemia variant for the first time in Saudi Arabia. An elderly Saudi man presented with pallor, massive splenomegaly, and moderate hepatomegaly. Hemoglobin was 7.7 g/dl, Platelets were 134 x109/l and white blood count was 140x1...
متن کاملDuration of response after interferon treatment of hairy cell leukemia.
Blood, Vol 75, No 12 (June 15). 1990: pp 2465-2468 times a week for an additional 18 months or until disease progression or intolerable toxicity. Response was evaluated on all 35 patients and was appropriately presented by prior treatment (none, splenectomy, and/or chemotherapy). The response rates achieved in this series appear similar to other reports. Durability of response was based on the ...
متن کاملTreatment of hairy cell leukemia with recombinant alpha 2 interferon.
Nine patients with progressive hairy cell leukemia were treated with subcutaneous injections of recombinant alpha 2 interferon (2 to 10 X 10(6) U/m2) three times weekly. Eight patients completed at least eight weeks of treatment and were evaluable; one patient with refractory thrombocytopenia died of an intracerebral hemorrhage after two doses of interferon. Seven of eight patients responded, w...
متن کاملGenomics of Hairy Cell Leukemia
Hairy cell leukemia (HCL) is a chronic mature B-cell neoplasm with unique clinicopathologic features and an initial exquisite sensitivity to chemotherapy with purine analogs; however, the disease relapses, often repeatedly. The enigmatic pathogenesis of HCL was recently clarified by the discovery of its underlying genetic cause, the BRAF-V600E kinase-activating mutation, which is somatically an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2014
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v124.21.5482.5482